Paper23908265
Designing the magic bullet? The advancement of immuno-PET into clinical use.
Wright BD and 1 other. J Nucl Med, 2013. Cited by 49 papers, by iCite.
Cite this record
ConductScience Library. Designing the magic bullet? The advancement of immuno-PET into clinical use. Papers, record 23908265. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23908265
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Positron-Emission Tomography | Major topic |
| Humans | |
| Iodine Radioisotopes | |
| Isotope Labeling | |
| Zirconium |
Source PubMed
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42588729 | Predicting Therapeutic Response to Antibody-Drug Conjugates Using Targeted PET Imaging: A Systematic Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588729 | PubMed |
| 37991639 | Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer. | EJNMMI Radiopharm Chem | 2023 | https://conductscience.org/library/papers/37991639 | PubMed |
| 36936995 | Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine. | Front Mol Biosci | 2023 | https://conductscience.org/library/papers/36936995 | PubMed |
| 36559316 | Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36559316 | PubMed |
| 36145664 | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36145664 | PubMed |
| 35563414 | Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35563414 | PubMed |
| 35314661 | Validation of In Vivo Nodal Assessment of Solid Malignancies with USPIO-Enhanced MRI: A Workflow Protocol. | Methods Protoc | 2022 | https://conductscience.org/library/papers/35314661 | PubMed |
| 34804069 | Noninvasive Immuno-PET Imaging of CD8+ T Cell Behavior in Influenza A Virus-Infected Mice. | Front Immunol | 2021 | https://conductscience.org/library/papers/34804069 | PubMed |
| 33466827 | Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124. | Molecules | 2021 | https://conductscience.org/library/papers/33466827 | PubMed |
| 33205364 | Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®. | EJNMMI Radiopharm Chem | 2020 | https://conductscience.org/library/papers/33205364 | PubMed |
| 33169605 | Polyazamacrocycle Ligands Facilitate 89Zr Radiochemistry and Yield 89Zr Complexes with Remarkable Stability. | Inorg Chem | 2020 | https://conductscience.org/library/papers/33169605 | PubMed |
| 32048177 | Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging. | Mol Diagn Ther | 2020 | https://conductscience.org/library/papers/32048177 | PubMed |
| 31667145 | An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care. | Quant Imaging Med Surg | 2019 | https://conductscience.org/library/papers/31667145 | PubMed |
| 31095372 | Multimodal Positron Emission Tomography Imaging to Quantify Uptake of 89Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. | Bioconjug Chem | 2020 | https://conductscience.org/library/papers/31095372 | PubMed |
| 30865493 | 89Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma. | Cancer Biother Radiopharm | 2019 | https://conductscience.org/library/papers/30865493 | PubMed |
| 30755811 | Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. | Am J Cancer Res | 2019 | https://conductscience.org/library/papers/30755811 | PubMed |
| 30370812 | Application of Immuno-PET in Antibody-Drug Conjugate Development. | Mol Imaging | 2018 | https://conductscience.org/library/papers/30370812 | PubMed |
| 29462554 | Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. | ACS Nano | 2018 | https://conductscience.org/library/papers/29462554 | PubMed |
| 29450576 | ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. | Eur J Nucl Med Mol Imaging | 2018 | https://conductscience.org/library/papers/29450576 | PubMed |
| 29363548 | Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. | Cancer Res | 2018 | https://conductscience.org/library/papers/29363548 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23908265
GET https://conductscience.org/api/papers/v1/23908265/cited_by?page=2